Completed Projects

Toxicity-Related Treatment Cessation in Newly Diagnosed Multiple Myeloma - Risk Factors and Survival

Researcher(s)

A/Prof Ji Hyun Lee, Dong-A University College of Medicine, Busan, Republic of Korea

Progress

Published in European Journal of Haematology, 16 September 2026

Investigating C-terminal telopeptide 1 (CTX-1) as a marker of high risk for progressing to active MM in smouldering MM (SMM) patients.

Researcher(s)

Dr Kate Vandyke, Research Fellow, University of Adelaide

Progress

Abstract presented for Myeloma Australia National Myeloma Scientific Workshop 2026

Real-World Comparison of Treatment Outcomes for Multiple Myeloma in Elderly Transplant Ineligible Patients Receiving First-Line VRd, Rd and VCd: Results From the Australian and New Zealand Myeloma and Related Diseases Registry

Researcher(s)

Dr Sarah Zhao (Haematology Registrar), New Zealand

Progress

Published in Clinical Lymphoma Myeloma and Leukemia: 8 August 2025

IMPROVE: Immunoglobulins in Myeloma Patients: Research into Outcomes, Variation in practice, and Epidemiology

Outcomes of Patients with Multiple Myeloma Post-BCMA Directed Treatment: An Australian Perspective

Researcher(s)

Dr Jessica Ling, Dr Habib Sadiqi (Registrar) and Dr Brad Augustson (Consultant Haematologist), Fiona Stanley and Sir Charles Gairdner Hospital

Progress

Presented at IMS and Blood 2025

Infection prophylaxis and infection outcomes in patients with myeloma

Researcher(s)

Dr Khai Li Chai, PhD student and Consultant Haematologist, Northern Health

Progress

Published in eJHaem 16 June 2024

Comparison of characteristics and outcomes of patients diagnosed with MM by traditional CRAB criteria versus "newer" biomarkers of malignancy (and high risk SMM using 20/20/20 criteria)

Researcher(s)

Prof Joy Ho, Clinical Professor and Senior staff specialist, Haematology, Royal Prince Alfred Hospital, Sydney

Progress

Manuscript accepted to British Journal of Haematology

Evaluation of zoledronic acid use in myeloma patients with renal impairment.

Researcher(s)

John Coutsouvelis- senior clinical pharmacist at the Alfred Hospital

Progress

Poster for internal Monash student event.

Pacific Islanders with MM in New Zealand compared to other ethnicities: characteristics, treatment and outcomes

Researcher(s)

A/Prof Hilary Blacklock, Consultant haematologist, Middlemore Hospital, Auckland, New Zealand

Progress

Presented at International Myeloma Workshop 2019, Boston, USA and Blood 2019, Perth. Published in Clinical Lymphoma, Myeloma and Leukemia: April 8th, 2022. Project complete

Real world outcomes according to the Revised (2) International Staging System (R2-ISS)

Researcher(s)

Dr Joanne L C Tan, Consultant Haematologist Alfred Hospital

Progress

Published in British Journal of Haematology: 2 November 2022

VCD vs VRD vs VTD as induction therapy for newly diagnosed MM pts. Real world experience in a retrospective Australian and Asia-Pacific analysis

Researcher(s)

Justin Ng- Haematology trainee at the Alfred Hospital.

Progress

Poster at IMS Meeting 2022

The Impact of Body Weight on Melphalan dosing in Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Master's thesis topic

Researcher(s)

Dervla O'Regan, Masters Student and Clinical Pharmacist, The Alfred Hospital, Melbourne

Progress

Masters thesis completed

The Myeloma Landscape in Australia and New Zealand (ANZ): The first years of the Myeloma and Related Diseases Registry (MRDR)

Researcher(s)

Dr Krystal Bergin, Consultant haematologist & PhD student, The Alfred Hospital, Melbourne

Progress

Published in Clinical Lymphoma, Myeloma and Leukemia: January 29, 2021. Project complete

Rates of Upfront Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (NDMM): Comparing ASCT recipients and non-recipients

Researcher(s)

Dr Krystal Bergin, Consultant haematologist & PhD student, The Alfred Hospital, Melbourne

Progress

Published in Bone Marrow Transplantation: 19 May 2021. Project complete.

Analysis of bortezomib-based therapy in non-transplant eligible multiple myeloma

Researcher(s)

A/Prof Peter Mollee (Consultant haematologist) and Dr Stephen Boyle (Registrar), Princess Alexandra Hospital, Brisbane

Progress

Poster presentation at the International Myeloma Workshop in Boston, Sept 2019. Published in European Journal of Haematology: June 15, 2021. Project complete.

Predictors of early mortality in multiple myeloma: Results from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR)

Researcher(s)

A/Prof Zoe McQuilten, School of Public Health and Preventive Medicine, Monash University (Consultant haematologist)

Progress

Published in British Journal of Haematology: June 9th 2022. Project complete.

Methylation biomarkers in plasma cell free DNA in myeloma

Researcher(s)

Prof Ian Morison, Professor of Pathology, Dunedin School of Medicine, University of Otago

Progress

M1000 Biobank request - analysis complete and report sent

Causes of death in patients with multiple myeloma

Researcher(s)

Rosalyn Cao, Master of Public Health student, Monash University

Progress

Presented at the National Myeloma Workshop 2020, Blood 2021, project complete.

Impact of daratumumab on real-world outcomes in multiple myeloma (MM)

Researcher(s)

Dr Sueh-li Lim, Prof Andrew Spencer, Consultant Haematologists, Alfred Hospital

Progress

Published research letter in British Journal of Haematology 2020

Comparison of patients with newly diagnosed MM who are transplant ineligible, receiving bortezomib versus lenalidomide

Researcher(s)

Natthida Khajornjiraphan, Master of Clinical Research Methods student, Monash University, and Clinical Trial Coordinator (Haematology), St Vincent's Hospital Melbourne

Progress

Analysis complete - presented at the National Myeloma Workshop 2020

Renal Impairment at diagnosis in myeloma: an analysis of patient characteristics, treatment, and impact on outcomes

Researcher(s)

Prof Joy Ho, Clinical Professor and Senior staff specialist, Haematology, Royal Prince Alfred Hospital, Sydney

Progress

Published 2019 - Project complete

Treatment patterns in relapsed / refractory MM in Australia

Researcher(s)

Dr Jessie Zhao, Registrar, Dorevitch Pathology, Melbourne

Progress

Oral presentation at Blood 2019 in Perth, Australia; project complete

Overview of imaging modalities in multiple myeloma - used for presentation on 18F-FDG-PET/CT to support uptake of the internationally preferred imaging modality in Australia

Researcher(s)

Dr Kylee McLachlan, Consultant Haematologist, Peter MacCallum Cancer Centre, Melbourne

Progress

Oral Presentation at Blood 2018 - Project complete